In a comparative trial conducted by Chen P et al., it was observed that carriers of the UGT1A1*6 and UGT1A1*28 polymorphisms exhibited significantly higher rates of complete remission in the context of cytarabine treatment for AML among 726 adult patients. The gene discussed is UGT1A1; the disease is acute myeloid leukemia.